Order a Sample of Single-Dose XOFLUZA

Sample a full course of flu treatment with single-dose XOFLUZA.1

 XOFLUZA® (baloxavir marboxil) Call Icon

Call 1-855-XOFLUZA to request a sample.

 XOFLUZA® (baloxavir marboxil) Or Icon
  XOFLUZA® (baloxavir marboxil) Or Icon
XOFLUZA® (baloxavir marboxil) Desktop Icon

On your desktop device, register or log in to the XOFLUZA Sampling Portal. Select a desired dose and electronically sign to request a sample.

What to Expect With Your Order

Your order will include:

  • One dose of either tablet of your choosing:
    • One 40-mg tablet for patients weighing <176 lb (<80 kg)
    • One 80-mg tablet for patients weighing ≥176 lb (≥80 kg)
  • A pack of XOFLUZA coupons to help your eligible patients save on XOFLUZA
  • XOFLUZA Brochure for Healthcare Providers
  • XOFLUZA dosing card

Annual sample limits and other restrictions apply.

Drug samples may not be sold, purchased, traded, or offered for sale, purchase, or trade, utilized to seek reimbursement or otherwise distributed in a manner not permitted by applicable law. A sample may only be distributed to practitioners who are licensed or authorized under applicable state law to prescribe XOFLUZA and likely to treat patients consistent with its FDA-approved indication. Genentech reserves the right to deny fulfillment of XOFLUZA sample requests for any reason.

XOFLUZA® (baloxavir marboxil) Coupon Icon

Help Your Patients Save


Your eligible patients may pay as little as $30 (up to $60 off) for XOFLUZA.
Terms and conditions apply.

Indication

XOFLUZA is an influenza virus polymerase acidic (PA) endonuclease inhibitor indicated for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours and who are:

  • Otherwise healthy, or
  • At high risk of developing influenza-related complications

XOFLUZA is also indicated for post-exposure prophylaxis (PEP) of influenza in patients 12 years of age and older following contact with an individual who has influenza.

 

Limitations of Use
Influenza viruses change over time, and factors such as the virus type or subtype, emergence of resistance, or changes in viral virulence could diminish the clinical benefit of antiviral drugs. Consider available information on drug susceptibility patterns for circulating influenza virus strains when deciding whether to use XOFLUZA.

Important Safety Information

Contraindications
XOFLUZA is contraindicated in patients with a history of hypersensitivity to baloxavir marboxil or any of its ingredients. Serious allergic reactions have included anaphylaxis, angioedema, urticaria, and erythema multiforme.

 

Warnings and Precautions

Hypersensitivity:
 Cases of anaphylaxis, urticaria, angioedema, and erythema multiforme have been reported in postmarketing experience with XOFLUZA.  Appropriate treatment should be instituted if an allergic-like reaction occurs or is suspected.

 

Risk of bacterial Infections: There is no evidence of the efficacy of XOFLUZA in any illness caused by pathogens other than influenza viruses. Serious bacterial infections may begin with influenza-like symptoms or may coexist with, or occur as, a complication of influenza. XOFLUZA has not been shown to prevent such complications. Prescribers should be alert to potential secondary bacterial infections and treat them as appropriate.

Adverse Reactions
The most common adverse reactions (≥1%) in clinical studies for acute uncomplicated influenza were diarrhea (3%), bronchitis (3%), nausea (2%), sinusitis (2%), and headache (1%).


The most common adverse reaction in a clinical study for post-exposure prophylaxis (PEP) was nasopharyngitis (6%).

 

Drug Interactions

Polyvalent cations:
 Coadministration with polyvalent cation-containing products may decrease plasma concentrations of baloxavir, which may reduce XOFLUZA efficacy. Avoid coadministration of XOFLUZA with dairy products, calcium-fortified beverages, polyvalent cation-containing laxatives, antacids, or oral supplements (e.g., calcium, iron, magnesium, selenium, or zinc).

 

Vaccines: The concurrent use of XOFLUZA with intranasal live attenuated influenza vaccine (LAIV) has not been evaluated. Concurrent administration of antiviral drugs may inhibit viral replication of LAIV and, thereby, decrease the effectiveness of LAIV vaccination. Interactions between inactivated influenza vaccines and XOFLUZA have not been evaluated.


For additional important safety information, please see the XOFLUZA full Prescribing Information.

You are encouraged to report side effects to Genentech by calling 1-888-835-2555 or to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088.